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Abstract
Background: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of
this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are
linked to clinical practice.
Methods: A non-exhaustive systematic review was conducted according to the three topics. No publication
restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the
main results and findings of the review was presented and discussed during three meetings (one for each
topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of
pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist
medical oncologists in renal cancer.
Results: The efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently
confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of
life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of
patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly
patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with
concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an
effective drug, in which quality of life (QoL) outcomes are valued above all.
Conclusions: This paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of
pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and
tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to
be safe in different patient profiles.
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Background
Renal cancer accounts for 2% of all cancers diagnosed in
adults, although the incidence is higher in developed
countries. Every year, approximately 295,000 new cases
are diagnosed, and around 134,000 deaths are recorded
[1, 2]. The most common kidney cancer in adults is
renal cell carcinoma (RCC), which accounts for 90% of
malignant kidney tumors; of these, an estimated 80–85%
are clear cell tumors. Other less commonly diagnosed
tumors include papillary and chromophobe RCC [3, 4].
Despite curative surgery of the localized tumor, it is esti-
mated that approximately 30% of patients will subse-
quently develop metastatic disease [5].
Clear cell RCC are highly vascularized tumors that accu-
mulate lipid and glycogen [6–8]. The identification of dys-
regulated signaling pathways in vascular endothelial
growth factor (VEGF) and the mammalian target of rapa-
mycin (mTOR) in the progression of RCC has led to the
development and approval of molecules targeting these
pathways for therapeutic purposes [9]. Tyrosine kinase
inhibitors (TKI) and mTOR inhibitors are now thera-
peutic options in first-, second- and third-line treatment
in patients with metastatic RCC (mRCC) [6, 10–12].
Pazopanib is a multikinase inhibitor which targets the
VEGF receptor (VEGFR), the platelet-derived growth
factor receptor (PDGFR) and c-Kit protein, inhibiting
angiogenesis [13–15]. It is indicated in adult patients
with mRCC, both as a first-line treatment and after pre-
vious treatment with cytokines [16].
Given the large volume of evidence that is generated
year after year in the field of oncology, publications that
review and collect the most relevant data help profes-
sionals involved in the management of patients to keep
informed of the latest developments, so reviews of the
literature in oncology, as in other therapeutic areas, are
relevant and necessary. On the other hand, it is known
that the real world practice is much more complex and
variable than the research environment. In addition, cli-
nicians may have different opinions about the relative
value of the published data, which may cause several
professionals to opt for very different attitudes to face
the same problem. Therefore, it could be interesting to
have documents containing the review of published data
along with expert opinions. This type of combined docu-
ments can be useful to know if published evidence is
transferred / reflected in routine clinical practice. More-
over, they can help to improve the knowledge and as a
consequence of the clinical practice, since they give a
global vision both “theoretical” (published data) and
“practical” (expert opinion), on a specific topic. Several
review papers on the evidence of pazopanib in the
first-line treatment of mRCC have been published in the
last 5 years [17–23]. However, no single document has
included data on the efficacy, tolerability and pharmaco-
kinetics of pazopanib, combined, moreover, with the
opinion of an expert group. The aim of this work was to
conduct a review of pazopanib and compare it with the
clinical practice. This review document presents the
Fig. 1 Right 3 Study methodology
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available evidence published to date on the three funda-
mental aspects of pazopanib in the first-line treatment
of mRCC: efficacy, tolerability and pharmacokinetics. It
also includes a qualitative survey among specialist med-
ical oncologists in renal cancer on certain aspects of
standard clinical practice and the management of mRCC
patients treated with pazopanib.
Methods
The methodology of this review article is summarized
in Fig. 1. A scientific committee was formed, consist-
ing of 3 specialist medical oncologists in kidney can-
cer, who, in an initial in-person meeting led by an
expert moderator, agreed on a series of clinical ques-
tions. Clinical questions were categorized into 3 main
sections: efficacy, safety, and pharmacokinetics of
pazopanib. A non-exhaustive systematic review of the lit-
erature in Medline was then conducted to identify publi-
cations that could answer these questions. Generic key
words employed were: “carcinoma, renal cell”[MeSH]
AND “pazopanib”[All Fields] AND “humans”[MeSH
Terms]. No publication date restrictions were imposed
and articles in English or Spanish were included. For the
pharmacokinetics section, a specific search was conducted
which also included the following key words: “pharmaco-
kinetics” OR “pharmacokinetic” OR “pharmacodynamics”
OR “pharmacodynamic” OR “pharmacology”. Each mem-
ber of the scientific committee selected publications of
interest for one of the sections. These articles were con-
sulted and synthesized in specific templates. The resulting
synthesis of articles was then used by a panel of another
10 specialist medical oncologists in renal cancer to draw
up the responses to the proposed clinical questions. These
responses were distributed and discussed, and a consensus
was reached during 3 in-person meetings; all meetings
were attended by a member of the scientific committee
and several members of the expert panel. At the same
meetings, a questionnaire on aspects of clinical practice
related to the evidence on pazopanib in the treatment of
mRCC was drawn up consensually (Table 1). The ques-
tionnaire was completed by 60 specialist medical oncolo-
gists in renal cancer, 68.3% of whom stated that they saw
10 or more mRCC patients a year, and 98.3% of whom
had 3 or more years of experience in the area. The com-
pletion of the questionnaire was considered implied con-
sent to participate. This document presents the evidence
gathered, the conclusions of the expert panel, and the
most relevant results obtained from the questionnaire.
Results and discussion
Pazopanib efficacy
Progression-free survival
Evidence on the effectiveness of pazopanib in the first-line
treatment of mRCC has been obtained from several
clinical trials which have shown a progression-free survival
(PFS) of between 8 and 11 months, either compared to
placebo or to sunitinib [14, 24]. The COMPARZ study
demonstrated the non-inferiority of pazopanib compared
to sunitinib in terms of PFS. This evidence is consistent
with that obtained in a retrospective comparative study
[25, 26] (Table 2) and also in the real-life retrospective
SPAZO study [25, 26] which showed a PFS of 11.1 months.
Other studies have reported PFS rates of between 10.5
and 14.1 months [19, 27–29].
Response rate
Response rate data are listed in Table 2. Response rates
based on the independent evaluations performed in the
VEG105192 and the COMPARZ studies were signifi-
cantly superior to those obtained with placebo and suni-
tinib, respectively. On the other hand, the overall
response rate with pazopanib in the SPAZO study [25,
26] was of 30.3%, showing, as in the case of PFS, high
consistency with published rates from clinical trials.
Recently, a post hoc exploratory analysis identified and
described the clinical characteristics of patients in COM-
PARZ who exhibited a long-term response to pazopanib
or sunitinib (patients with complete response (CR) / par-
tial response (PR) or PFS ≥ 10 and ≥ 18 months), showing
PFS ≥ 10 months in 31.4% patients and PFS ≥ 18 months
in 14.2% patients, and a shorter time to response with
pazopanib compared with sunitinib (11.9 vs 17.4 weeks).
Overall survival
Mean overall survival (OS) in the VEG105192 study was
not statistically significant (Table 2). This may be ex-
plained by the frequent and early switching of patients
in the placebo arm to the pazopanib arm, and the inclu-
sion of patients both previously treated and previously un-
treated with cytokines [14, 30, 31]. In the COMPARZ
study, no significant differences in mean OS were ob-
served between pazopanib and sunitinib (Table 2), either
in the main study or the latest update: 28.3 vs.
29.1 months, respectively [32]. In various real-world clin-
ical practice studies, a mean OS of 19–40.8 months has
been described, probably depending on the proportion of
patients with poor prognosis included in the sample [27–
29, 33]. Recent studies with the new second-line treat-
ments recommended by the ESMO guidelines, such as
nivolumab and cabozantinib, show that after the adminis-
tration of pazopanib in first line, the median OS for cabo-
zantinib in second line is 22 months, while median OS for
nivolumab has not been reached at the time of publication
of this manuscript [34–36].
Quality of life
In the pre-planned analysis of quality of life (QoL) in the
VEG105192 study, no significant differences were
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Table 1 Questionnaire on the first-line use of pazopanib in clinical practice
Question Response options
1a Is achieving a complete response or a partial response with pazopanib in first-line treatment directly
correlated with better OSa?
1 (strongly disagree)
4 (strongly agree)
1b Is achieving a complete or partial response with pazopanib in first-line treatment directly correlated
with better PFSb?
1 (strongly disagree)
4 (strongly agree)
2 Even if there is no impact on OS, is the longer PFS in first-line treatment with pazopanib sufficient for
it to be considered as a standard treatment option?
1 (strongly disagree)
4 (strongly agree)
3 Should OS be considered as a primary objective in first-line studies? a) Yes
b) No
4 When selecting pazopanib as a first-line treatment, to which parameter do you give more importance
in daily clinical practice?
a) OS
b) PFS
c) cQoL
5 Does reducing the dose of pazopanib compromise its efficacy? 1 (strongly disagree)
4 (strongly agree)
6 When prescribing a treatment, do you inform the patient about the different first-line treatment
options in order to take into account their opinion and preference?
1 (strongly disagree)
4 (strongly agree)
7a Is pazopanib an appropriate first-line treatment for patients with clear cell carcinoma, ECOGd 0, and no
significant comorbidities?
1 (strongly disagree)
4 (strongly agree)
7b Is pazopanib an appropriate first-line treatment for patients with brain metastases? 1 (strongly disagree)
4 (strongly agree)
7c Is pazopanib an appropriate first-line treatment for patients with concomitant cardiovascular disease? 1 (strongly disagree)
4 (strongly agree)
7d Is pazopanib an appropriate first-line treatment for patients with concomitant liver disease? 1 (strongly disagree)
4 (strongly agree)
7e Is pazopanib an appropriate first-line treatment for patients with non-clear cell histologies? 1 (strongly disagree)
4 (strongly agree)
7f Is pazopanib an appropriate first-line treatment for patients with moderate to severe renal failure
(CrCle ≤ 30)?
1 (strongly disagree)
4 (strongly agree)
7 g Is pazopanib an appropriate first-line treatment for patients with ECOG ≥2? 1 (strongly disagree)
4 (strongly agree)
7e Is pazopanib an appropriate first-line treatment for patients with a poor prognosis? 1 (strongly disagree)
4 (strongly agree)
7f Is pazopanib an appropriate first-line treatment for patients with asymptomatic heart disease and
fLVEF < 50%?
1 (strongly disagree)
4 (strongly agree)
8 When starting treatment with pazopanib in patients treated with oral anticoagulants, what do you
do in your standard clinical practice?
a) Change treatment to gLMWH
b) Continue hOAC treatment
9a With regard to patient age and pazopanib treatment, indicate your level of agreement with the
following statement: “I do not prescribe pazopanib in patients older than 80 years of age”
1 (strongly disagree)
4 (strongly agree)
9b With regard to patient age and pazopanib treatment, indicate your level of agreement with the
following statement: “In patients over 70 years of age, I prescribe treatment at a dose of
800 mg/day”.
1 (strongly disagree)
4 (strongly agree)
10 If biomarkers for pazopanib response were available, which would be most useful for you in your
daily clinical practice?
a) Biomarkers predicting toxicity
b) Biomarkers predicting efficacy
11 With regard to tolerability, place in order of importance, from highest to lowest, the following
factors to be taken into account when prescribing pazopanib.
a) Functional status
b) Concomitant diseases
c) Age
d) Social support
12 Is it advisable to temporarily suspend treatment with pazopanib, and to continue with radiological
monitoring, in order to reduce pazopanib toxicity (stop-and-go strategy)?
1 (strongly disagree)
4 (strongly agree)
13a If pazopanib toxicity develops, what do you do in the case of grade 2 gastrointestinal toxicity? a) Maintain the dose
b) Reduce the dose
c) Discontinue treatment
13b If pazopanib toxicity develops, what do you do in the case of grade 3–4 gastrointestinal toxicity? a) Maintain the dose
b) Reduce the dose
c) Discontinue treatment
13c If pazopanib toxicity develops, what do you do in the case of grade 1–2 liver toxicity (AST/ALT 2.5 a) Maintain the dose
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observed between the QoL with pazopanib or placebo,
as assessed using the EORTC-QLQ-C30 and EQ-5D
questionnaires and the EQ-5D visual analog scale [14].
The COMPARZ study also evaluated patient QoL, ob-
serving a significant improvement with pazopanib in 11
of the 14 domains that assessed health-related quality of
life (HRQoL) during the first 6 months of treatment
[24]. In the PISCES study (a patient preference study),
HRQoL was evaluated using the Functional Assessment
of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
scale: pazopanib obtained a 2.5-point higher score than
sunitinib (95% CI: 0.92–4.07; p < 0.002). The Supple-
mentary Quality of Life Questionnaire (SQLQ) question-
naire also showed better results with pazopanib in 5
parameters [37, 38]. Finally, in a post-hoc analysis, a
trend towards a lower risk of experiencing a > 20% loss
of QoL was observed with pazopanib compared to pla-
cebo [39].
Expert opinion in standard clinical practice
Evidence published on the effectiveness of pazopanib is
consistent and positions pazopanib as a standard treat-
ment option. In view of the positive results for pazopa-
nib in terms of OS and PFS, we asked the experts who
completed the questionnaire about how these parame-
ters relate with complete or partial response obtained
with pazopanib, and how important these parameters
are when considering pazopanib as an initial treatment
option. In total, 85% of respondents agreed or strongly
agreed that the complete or partial response rates
achieved with pazopanib are directly correlated with a
higher PFS, while 57.5% of respondents associated
these parameters with a longer OS. In addition, 95%
of respondents agreed that the longer PFS in first line
is sufficient to consider pazopanib as a standard treat-
ment option.
Almost 50% of the specialists who responded to the
questionnaire stated that they give more importance to
QoL as an efficacy parameter than to PFS or OS when
selecting pazopanib as first-line treatment. In the case of
complete response with pazopanib, 87.5% of respondents
stated that they would maintain the therapeutic regimen,
while 12.5% would discontinue it.
Pazopanib tolerability
Most adverse events recorded in the VEG105192 study
with pazopanib were grade 1 or 2; 52% of patients had
diarrhea; 40% arterial hypertension (AHT); 38% hair de-
pigmentation, 26% nausea; 22% anorexia; and 21%
vomiting [14]. The incidence of grade 3 or 4 adverse
events was 7% for placebo and 33% for pazopanib, the
most common being arterial hypertension and diarrhea.
The safety profiles of pazopanib and sunitinib in the
COMPARZ study were significantly different [24] (Table
3). Patients who received pazopanib showed lower inci-
dences of fatigue, hand-foot syndrome, stomatitis,
leukopenia, thrombocytopenia, neutropenia, and anemia.
No differences were observed in the incidence of cardio-
vascular adverse events, myocardial infarction or ische-
mia. In contrast, a higher incidence of elevated alanine
aminotransferase (ALT) levels was reported with pazopa-
nib. These differences in side effects between the two
Table 1 Questionnaire on the first-line use of pazopanib in clinical practice (Continued)
Question Response options
times the normal value)? b) Reduce the dose
c) Discontinue treatment
14 If the patient shows complete response to pazopanib, what do you do in your standard clinical
practice?
a) Maintain the dose
b) Adjust the therapeutic regimen
c) Discontinue treatment
aOS: overall survival; bPFS: progression-free survival; cQoL: quality of life; dECOG: Eastern Cooperative Oncology Group; eCrCl: creatinine clearance; fLVEF: left
ventricular ejection fraction; gLWMH: low molecular weight heparin; hOAC: oral anticoagulants
Table 2 Pazopanib efficacy data from comparative studies
VARIABLE STUDY DRUGS OUTCOME STATISTICS
Progression-free survival VEG105192 [14] Pazopanib vs placebo 11.1 vs 2.8 months HRa=0.40; 95% CIb: 0.27–0.60
COMPARZ [24] (non-inferiority) Pazopanib vs sunitinib 8.4 vs 9.5 months HR = 1.05; 95% CI: 0.90–1.22
International mRCC Database
Consortium (IMDC) [26]
Pazopanib vs sunitinib 8.3 vs 8.3 months (HR = 1.08; 95% CI: 0.98–1.19)
Response rate VEG105192 Pazopanib vs placebo 30% vs 3% Pazopanib: 95% CI: 25.1–35.6
Placebo: 95% CI: 0.5–6.4
COMPARZ (non-inferiority) Pazopanib vs placebo 31% vs 25% p = 0.003
Overall survival VEG105192 [14] Pazopanib vs placebo 22.9 vs 20.5 months HR = 0.91; 95% CI: 0.71–1.16
COMPARZ (non-inferiority) Pazopanib vs sunitinib 28.4 vs 29.3 months HR = 0.91; 95% CI: 0.76–1.08
aHR: hazard ratio bCI: confidence interval;
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drugs are maintained in patients who require dose ad-
justment during treatment: the incidence of hematologic
adverse events and palmar-plantar erythrodysesthesia
was higher in the sunitinib group compared to the pazo-
panib group, whereas scant differences were observed in
diarrhea, fatigue, and hypertension [40].
Safety data from the pivotal studies were subsequently
confirmed in real-world clinical practice. Table 4 gathers
the main findings regarding to adverse events in three
studies. In these studies adverse events were evaluated
according to Common Terminology Criteria for Adverse
Events (CTCAE). All grades adverse events were re-
corded in the study by Matrana et al and US cohort
study. Only 3 and 4 grades are presented in SPAZO pub-
lication. Matrana et al. reported a study in patients
treated with pazopanib after progression on first-line tar-
geted treatment, in which 91% of the adverse events
were grade 1 or 2, and no treatment-related deaths
occurred [28].
Neither deaths due to toxicity nor unexpected toxicities
were reported in the Spanish SPAZO study. Although tox-
icity, especially low-grade toxicity, could have been under-
estimated as this was a retrospective study [25], the
toxicity data for pazopanib in standard clinical practice
are lower than those reported in clinical trials. This may
due to the growing body of experience among specialists
in the management of toxicities associated with renal can-
cer treatments, confirmed in the American cohort study,
in which dose adjustment was reported in 17% of the pa-
tients [33], a lower percentage than reported in the COM-
PARZ study, along with a discontinuation rate of 24% and
a mean daily dose of 664.9 mg [24].
Special populations
To date, no data have been published on the use of
pazopanib in patients with heart disease, although the
potential cardiovascular adverse effects of pazopanib
should be taken into account when prescribing pazopa-
nib in patients with this profile. In clinical trials, 40–46%
of patients had arterial hypertension [14, 24], although
the incidence of cardiac dysfunction was less than 0.5–
1% [16]. Blood pressure on starting treatment should be
lower than 140/90 mmHg and if a patient develops se-
vere hypertension or a hypertensive crisis, antihyperten-
sive therapy should be administered, and the treatment
should be suspended and restarted at a reduced dose, ac-
cording to clinical criteria [16]. No evidence is available
in patients treated with oral anticoagulants (OAC), so if
treatment is continued, the patient should be monitored
closely.
No specific evidence is available on the use of pazopa-
nib in patients with liver disease. Although cases of ele-
vated ALT and AST have been reported, concomitant
elevations of alkaline phosphatase or bilirubin are not
generally observed [16]. In this population, it is recom-
mended that liver function tests are performed before
and during treatment with pazopanib. In case of mild or
moderate liver failure (LF), the indications in the sum-
mary of product characteristics on administration and
patient monitoring should be followed. In patients with
moderate LF, the recommended dose is 200 mg pazopa-
nib once a day. However, pazopanib is not recom-
mended in patients with severe LF.
The pivotal trials of pazopanib included patients with
renal impairment (RI), but evidence in patients with cre-
atinine clearance (CrCl) < 30 ml/min is limited. Good
tolerability and a low incidence of serious adverse events
were observed in a retrospective study of 9 patients with
end-stage renal disease [41]. Some studies have included
patients with mRCC on hemodialysis treated with TKI,
in whom pazopanib was safe and effective and increased
the life expectancy [42, 43]. Isolated proteinuria is not
an indication for dose reduction, unless it is within the
Table 3 Percentage of patients with adverse effects observed in
the COMPARZ study
ADVERSE EFFECT PAZOPANIB SUNITINIB
Fatigue
Any grade 50% 63%
Grade 3–4 10% 17%
Hand-foot syndrome
Any grade 29% 50%
Grade 3–4 6% 11%
Stomatitis
Any grade 14% 27%
ALTb 60% 43%
Fatal AEas 2% 3%
Fatal treatment-related AEs 3 cases 8 cases
aAE: adverse events; bALT: alanine aminotransferase
Table 4 Percentage of patients with adverse effects in real-world
studies
Adverse effect Matrana [28]* US cohort [33]* SPAZO [25]**
Fatigue 44% 56% 7.7%
ASTa/ALTb 35% 3.9%/7.8%
Diarrhea 30% 52% 3.6%
Hypothyroidism 18%
Nausea/vomiting 17% 40%/44% −/1.1%
Arterial hypertension – 27% 4%
Anemia 2.6%
Dropout rate 12% 11.9%
aAST aspartate aminotransferase; bALT alanine aminotransferase
*All grades adverse events according to CTCAE; **Only grade 3–4 adverse
effects were reported
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nephrotic range (> 3.5 g/day), or presents with edema,
hyperlipidemia, or hypoalbuminemia [44].
Expert opinion in standard clinical practice
The results of the questionnaire survey show disparate
opinions with regard to actions to be taken in the event
of toxicity: 45% of the participants were of the view that
temporarily suspending treatment with pazopanib could
be an option to consider, while the other 55% disagreed.
These differences may initially be explained by some
vagueness regarding the type or grade of the toxicity in
question; however, similar disparity was also observed in
successive questions despite a more specific description
of the situations. In the case of grade 2 gastrointestinal
(GI) toxicity (4–6 bowel movements), half of the respon-
dents stated that they would not reduce the dose, while
the other half stated that they would, while for grade 3
or 4 GI toxicity, 57.5% stated that they would reduce the
dose and the remaining 42.5% would discontinue treat-
ment. Results also differed in the case of grade 1 or 2
liver toxicity. Lastly, in patients receiving OACs, most
experts stated that they would switch treatment to low
molecular weight heparins (LMWH), and only 15%
would reduce the OAC dose.
It was also noted in the questionnaire results that the
patient’s functional status and comorbidities are consid-
ered relevant when prescribing pazopanib. Ninety per-
cent of experts considered these factors as quite or very
important to take into account. While 65% considered
functional status as very important, the presence of co-
morbidities was considered very important by 30%.
Moreover, patient age and available social support were
considered as of little or no importance by 90% of the
respondents.
Efficacy and safety of pazopanib in different patient
profiles
Risk groups
In the subgroup analysis of the COMPARZ study [24],
the non-inferiority results for pazopanib compared to
sunitinib in terms of PFS were independent of the risk
groups, whether evaluated by the Memorial Sloan Ket-
tering Cancer Center (MSKCC) classification [45] or the
International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) [46]. According to the MSKCC,
mean PFS in low-risk patients with pazopanib was
13.7 months, 8.3 months in intermediate-risk patients,
and 3.0 months in high-risk patients [47].
In the SPAZO study, the IMDC risk criteria were vali-
dated in first-line treatment with pazopanib, and efficacy
and safety were demonstrated in all groups. In total,
19.4% of patients treated with pazopanib had a favorable
prognosis, 57.2% intermediate, and 23.4% poor progno-
sis. Significant differences in PFS were observed in the 3
risk groups: 32.4 months in patients with a favorable
prognosis, 11.1 months in the intermediate prognosis
group, and 4 months in those with a poor prognosis
[25]. In a recent observational study in which 12% of pa-
tients had an Eastern Cooperative Oncology Group
(ECOG) score of 2 or higher, median PFS and OS were
12.5 and 26.5 months, respectively, in patients with
intermediate/favorable risk; and 2.4 and 7.2 months in
patients with a high risk, respectively [48].
Recently, an update of SPAZO 2 study results was pre-
sented in ESMO 2017. SPAZO 2 is an extension and up-
date of SPAZO 1 trial with a total series of 530 patients
in 50 centres treated in 1st line with pazopanib and a
median follow up of 39.2 months. Population is some-
what different from SPAZO 1 trial with regard to the
proportion of IMDC prognostic subgroups (14.2% favor-
able, 61.9% intermediate and 24.9% poor prognosis). Re-
sults show a median PFS 9.8 months for the whole
population, and 19.1, 10.4 and 5.2 months for favorable,
intermediate and poor prognosis populations, respectively.
Median OS were 19.6 months for the whole population,
and 37.2, 20.8 and 7.2 for the favorable, intermediate, and
poor prognosis populations, respectively. Relative risks
were 32.9 for the whole population, and 58.9, 35.2 and
22.5% for the favorable, intermediate and poor prognosis
populations, respectively. In this study, eligibility for clin-
ical trials was tested as a prognostic factor. The study con-
firms the effectiveness of pazopanib in mRCC in the real
world setting and concludes that ineligibility might be
considered as a prognostic factor for PFS and OS (HR:
1.35; 95% CI 1.05–1.73) [49].
Drug tolerability was not related with prognostic
groups in any of the studies reviewed. However, the re-
sults of the observational studies which included pa-
tients with a worse prognosis or with ECOG 2 or higher
[48] are similar to those obtained in the VEG105192 [14]
and COMPARZ clinical trials [24].
Age
In registrational studies, 33% of the patients were older
than 65 years of age, 3% were over 75, and patients aged
up to 83 years of age were recruited [14, 16]. Elderly pa-
tients were also included in the COMPARZ and PISCES
studies [24, 37]. Although no conclusions can be drawn
due to the small number of elderly patients included in
these trials, there do not appear to be any differences in
effectiveness compared to sunitinib, and the safety pro-
file among patients receiving pazopanib was similar, re-
gardless of their age.
Functional status and other factors
In general, treatments show better PFS outcomes in pa-
tients with good prognosis, ECOG performance status of
0, and a period of 1 year or more between the initial
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diagnosis and treatment for metastatic disease [50]. In
the subgroup analysis of the COMPARZ study, PFS out-
comes were similar for both treatments, regardless of
the ethnicity, geographical origin or Karnofsky perform-
ance status of patients [24]. Although no specific ana-
lyses have been conducted, several observational studies
have included patients with poor prognostic variables
(ECOG > 2, patients diagnosed less than 1 year previ-
ously, 3 or more MSKCC risk factors or 3 or 4 IMDC
risk factors, histologies other than clear cell renal carcin-
oma, brain metastases, advanced age, or comorbidities),
in which pazopanib has shown efficacy results consistent
with those published in clinical trials [25, 29, 51, 52].
Expert opinion in standard clinical practice
Pazopanib has shown clinical benefit in all risk groups, re-
gardless of age, tumor histology, location of metastases,
and functional status or ECOG score. In this respect, the
experts completing the questionnaire were asked how they
perceived the appropriateness of using pazopanib in differ-
ent patient profiles, depending on comorbidities, progno-
sis, site of metastases, or functional status. In total, 95% of
respondents felt that pazopanib is a suitable option for the
treatment of patients with clear cell histologies, no comor-
bidities, and ECOG 0. Between 80 and 85% of respondents
agreed that pazopanib was appropriate for use in the
first-line treatment of patients with brain metastases, car-
diovascular comorbidities, or ECOG of 2 or greater. Al-
most 80% saw pazopanib as a first-line treatment in
patients with moderate-to-severe RI. Although, as out-
lined above, the available evidence is insufficient to advise
against or contraindicate the use of pazopanib in the fol-
lowing cases, more than half of participants did not con-
sider it as an appropriate first-line treatment in patients
with concomitant liver disease, non-clear cell histology, or
poor prognosis (Fig. 2). With regard to the appropriate-
ness of using pazopanib in elderly patients, almost all re-
spondents considered that patients over the age of
80 years are candidates for treatment with pazopanib, and
almost 90% agreed that doses of 800 mg/day could be
prescribed in patients older than 70 years. This opinion
was consistent with the populations of patients in-
cluded in clinical trials and observational studies, which
may reassure clinicians’ performance in this specific
group of patients.
Efficacy and safety biomarkers and polymorphisms
Biomarkers
The discovery of biomarkers can be of use in predicting
inter-patient differences in the efficacy and safety of an-
tineoplastic agents and for identifying patients who are
resistant to treatment. If the right drug is given to the
right patient, the chances of response might increase, or
the appearance of certain adverse reactions might be
predicted, helping to achieve greater therapeutic success
rates. Unfortunately, identifying these markers in the
early stages of clinical development of the drugs remains
a challenge, and they are generally identified when the
medications have been administered to more extensive
patient populations.
Arterial hypertension has been considered a biomarker
of response to angiogenesis inhibitors [53]. In the case of
pazopanib, a subanalysis of the COMPARZ study noted a
trend (not statistically significant) towards a longer PFS in
patients with a higher grade of systolic hypertension in
weeks 4 and 12 of treatment (p = 0.06 and 0.07, respect-
ively), as well as a trend towards longer OS in patients with
higher systolic hypertension in week 4 (p = 0.062) [54].
Fig. 2 Results of the questionnaire on the use of pazopanib in standard clinical practice according to patient profile (CrCl: creatinine clearance;
ECOG: Eastern Cooperative Oncology Group: LVEF: left ventricular ejection fraction)
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High baseline plasma concentrations of interleukin
(IL)-6, IL-8, osteopontin and VEGF have been associated
with an increased response to pazopanib in terms of OS,
while high baseline levels of hepatocyte growth factor
(HGF) have been associated with a lower OS in patients
receiving pazopanib [55]. In another publication, high
plasma concentrations of IL-8, osteopontin, HGF and
tissue inhibitor of metalloproteinases 1 (TIMP1) were
associated with a lower PFS in patients receiving pazopa-
nib, while IL-6, IL-8 and osteopontin were also associ-
ated with a lower PFS in the placebo group. This latter
finding might suggest a relationship between these 3
markers and RCC progression, rather than an associ-
ation with response to pazopanib [56]. A recent subana-
lysis in patients in the COMPARZ study found that a
mutation in the PBRM1 suppressor gene is associated
with a better response to TKI, in the form of increased
PFS and OS, as it seems to enhance the pro-angiogenic
microenvironment of RCC. In contrast, the BAP1 mu-
tation is associated with decreased angiogenic signaling
and a poorer outcome for TKIs, manifesting as a
shorter OS [57].
Polymorphisms
VEGF genotypes s833061TT, rs2010963CC, and rs699
947CC have been associated with a greater clinical bene-
fit in patients receiving pazopanib [58]. Polymorphisms
in the IL-8 gene and hypoxia-inducible factor 1A
(HIF-1A) have been associated with PFS in pazopanib-
treated patients, and polymorphisms in the HIF-1A, nu-
clear receptor subfamily 1, group I, member 2 (NR1I2),
and VEGFA genes have been associated with response
rates [59]. The rs1126647 genotype of the IL-8 gene has
been associated with a shorter OS [60] and the variant
rs34231037 in the VEGFR2 gene has been associated
with greater sensitivity to pazopanib treatment [61].
The UGT1A1 TA-repeat polymorphism (Gilbert’s syn-
drome) is significantly associated with increased bilirubin
levels in patients treated with pazopanib [62]. TA7/TA7
homozygous or TA6/TA7 heterozygous patients can show
an increased risk of developing hyperbilirubinemia when
receiving pazopanib [63]. The VEGFR2 gene + 1416 T >A
(His472Gln) polymorphism has been associated with in-
creases in blood pressure during treatment with pazopa-
nib, particularly in AA homozygous patients. Similar
results were observed with the VEGFA gene -2578C > A,
-1498C > T and -634G > C polymorphisms [64]. Specific
polymorphisms such as the rs2858996/rs707889 in the
HFE gene may be associated with reversible ALT elevation
in patients treated with pazopanib [65].
Expert opinion in standard clinical practice
The identification of biomarkers that can predict re-
sponse to antiangiogenic therapy may be of vital
importance to mRCC patients. At present, no bio-
markers that predict response to treatment with pazopa-
nib have been validated prospectively, and as such, these
data cannot be applied to clinical practice. In the ques-
tionnaire, 95% of respondents felt that if biomarkers
were identified, those predicting efficacy would be more
useful than those which predicted safety.
Pazopanib pharmacokinetics
According to the phase I study in patients with solid
tumors treated with pazopanib, maximum plasma con-
centration (Cmax) and area under the curve (AUC0–24)
on day 1 increased as the pazopanib dose increased, up
to the maximum dose of 2000 mg/day. However,
steady-state exposure is achieved at a dose of pazopanib
800 mg/day [66].
Pazopanib is extensively bound to plasma proteins
(99.9%), regardless of its plasma concentration [67], and
it is primarily excreted as unchanged drug in feces.
In the phase I study, a minimum plasma concentration
(Cmin) of 15 mg/l or more was associated with a partial
response [66]. A Cmin of > 20.5 mg was subsequently as-
sociated with a greater reduction in tumor size (37.9%
vs. 6.9% with a Cmin < 20.5 mg/l) and a longer PFS
(52 weeks vs. 19.6 weeks with a Cmin < 20.5 mg/L) [68].
The greatest variability among patients treated with
pazopanib is caused by the ingestion of fat in the diet, as
this factor may double the AUC or Cmax of the drug.
Therefore, it is recommended that pazopanib is adminis-
tered 1 h before or 2 h after meals. Other factors, such
as age, race or gender, do not seem to be related to
inter-patient variability [69, 70]. The use of concomitant
medications that alter gastric pH is also associated with
inter-patient variability [68]. Genetic variability may also
affect the response to pazopanib, although as noted
above, no validated biomarkers are currently available.
The concomitant administration of cytochrome P450
CYP3A4 inhibitors and pazopanib results in an increase
in plasma concentrations, because pazopanib is a sub-
strate of CYP3A4 and, to a lesser extent, CYP1A2 and
CYP2C8 [71]. In contrast, CYP3A4 activity may be en-
hanced in patients with the NR1/2 T allele, resulting in
increased pazopanib clearance [59].
The pazopanib dose of 800 mg daily was selected on
the basis of the phase II and III study data, plasma con-
centrations associated with the clinical and biological ef-
fects in preclinical models and in patients with solid
tumors [72, 66], and because the steady-state plasma
concentration of 20.5 μg/ml is associated with longer
PFS and reductions in tumor size. Even so, pazopanib
adverse events are dependent on plasma concentration
[68], so the dose sometimes needs to be reduced, initially
to 600 mg and then to 400 or 200 mg, if necessary [16].
In this context, it has been observed that the percentage
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of patients within the target window during fixed dosing
is not significantly different from that of patients whose
doses are adjusted [73]. On the other hand, a subanalysis
of the COMPARZ study noted a longer PFS with both
drugs in patients requiring a dose adjustment for the
management of toxicities, suggesting that dose reduc-
tions or temporary treatment interruptions do not affect
efficacy [40].
Expert opinion in standard clinical practice
If adverse effects appear, adjusting the pazopanib dose
reduces toxicity and does not appear to compromise effi-
cacy. In contrast to reports, the perception of most ex-
perts surveyed (62.5%) is that reducing the pazopanib
dose compromises efficacy.
Conclusions
This paper offers a comprehensive and critical summary
of three important aspects of pazopanib in the treatment
of mRCC: efficacy, tolerability, and pharmacokinetics. It
also includes data on special populations and a summary
of potential future biomarkers. The efficacy results of
pazopanib in terms of PFS, OS and response rates are
consistent across all studies.
Pazopanib is a treatment with an acceptable safety
profile. Its QoL and tolerability results offer certain ad-
vantages when compared with other therapeutic alterna-
tives, and its use appears to be safe in different patient
profiles, including the elderly and patients with heart
disease, mild or moderate liver failure, or poor func-
tional status. Before pazopanib is indicated, the patient
must be fully assessed, taking into account their func-
tional status, comorbidities, and concomitant medica-
tions, rather than simply assessing patient age, thus
minimizing toxicities. The first dose reduction in the
event of adverse effects with pazopanib is from 800 mg
to 600 mg, and this adjustment does not appear to com-
promise efficacy. Intra- and inter-patient variability is
mainly associated with gastric pH and food intake.
The questionnaire allowed us to compare the available
evidence on the use of pazopanib with the perceptions
of the drug among a group of medical oncologists, all
experts in the treatment of RCC. The results of the
questionnaire have shown that pazopanib is perceived as
an effective drug, in which QoL outcomes are valued
above all.
After reviewing the efficacy and safety data of the
drug, this paper concludes that pazopanib can be used
in patients of any prognostic group, functional status,
and age. Observational studies also show that pazopanib
is effective in patients with non-clear cell histology, brain
metastases, and in different metastatic sites, although
the opinion of the experts consulted may vary, as in the
case of patients with liver diseases. In view of the above,
we can conclude that the experts view pazopanib as a
good first-line treatment option in the majority of pa-
tients with mRCC.
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